Patents by Inventor Claus Meese

Claus Meese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7282515
    Abstract: This invention relates to azaspiro compounds and their use as medications especially for the treatment of chronic, chronic-phlogistic and/or neuropathic pain. Compounds that lend themselves particularly well to the production of analgesics include 1,3-diazaspiro[4.5]decane-2,4-dion and 1,3-diazaspiro[4.5]decane-2,4-dithion.
    Type: Grant
    Filed: September 7, 2004
    Date of Patent: October 16, 2007
    Assignee: Schwarz Pharma AG
    Inventors: Claus Meese, Norma Selve, Dirk Schmidt
  • Patent number: 7230030
    Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Type: Grant
    Filed: January 27, 2004
    Date of Patent: June 12, 2007
    Assignee: Schwarz Pharma AG
    Inventors: Claus Meese, Bengt Sparf
  • Publication number: 20060270738
    Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Type: Application
    Filed: August 10, 2005
    Publication date: November 30, 2006
    Inventors: Claus Meese, Bengt Sparf
  • Publication number: 20060029673
    Abstract: The invention relates to a device for transdermally administering a compound of formula (I), wherein A represents hydrogen or deuterium, R represents a group selected among C1-4alkyl, C3-10cycloalkyl, or phenyl, each of which can be substituted by C1-3 alkoxy, fluoride, chlorine, bromine, iodine, nitro, amino, hydroxy, oxo, mercapto, or deuterium, the C atom marked by * (asterisk) being provided in the R configuration. The invention is characterized in that the compound of general formula (I) is provided in a polymer matrix and is released at a dose of 0.5 to 20 mg per day through human skin. The invention further relates to the use of said compounds of formula (I) for producing transdermal medicaments.
    Type: Application
    Filed: April 3, 2004
    Publication date: February 9, 2006
    Applicant: Schwarz Pharma AG
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Publication number: 20060014832
    Abstract: The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6 alkyl, C3-10 cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterised in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments.
    Type: Application
    Filed: April 3, 2004
    Publication date: January 19, 2006
    Applicant: Schwarz Pharma AG
    Inventors: Armin Breitenbach, Claus Meese, Hans-Michael Wolff, Roland Drews
  • Publication number: 20050288351
    Abstract: This invention relates to azaspiro compounds and their use as medications especially for the treatment of chronic, chronic-phlogistic and/or neuropathic pain. A compound that lends itself particularly well to the production of analgesics is 2-azaspiro[4.6]undecane-3-thion.
    Type: Application
    Filed: September 7, 2004
    Publication date: December 29, 2005
    Applicant: Schwarz Pharma AG
    Inventors: Claus Meese, Norma Selve, Dirk Schmidt
  • Publication number: 20050119319
    Abstract: This invention relates to azaspiro compounds and their use as medications especially for the treatment of chronic, chronic-phlogistic and/or neuropathic pain. Compounds that lend themselves particularly well to the production of analgesics include 1,3-diazaspiro[4.5]decane-2,4-dion and 1,3-diazaspiro[4.5]decane-2,4-dithion.
    Type: Application
    Filed: September 7, 2004
    Publication date: June 2, 2005
    Applicant: Schwarz Pharma AG
    Inventors: Claus Meese, Norma Selve, Dirk Schmidt
  • Patent number: 6858650
    Abstract: The present invention concerns highly pure, crystalline, stable compounds of novel derivatives of 3,3-diphenylpropylamines in the form of their salts, a method for the manufacture and highly pure, stable intermediate products. The method is in particular characterized by regio- and chemoselectivity and high yield. Salts of phenolic monoesters of 3,3-diphenylpropylamines are provided, that are particularly well-suited for use in pharmaceutical formulations. Preferred compounds are R-(+)-2-(3-diisopropylamino-1-phenyl-propyl)-4-hydroxymethylphenylisobutyrate ester hydrogen fumarate and R-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethylphenylisobutyrate ester hydrochloride hydrate. Furthermore, stable, crystalline intermediate products that are essential for obtaining the abovementioned salts are provided. A preferred intermediate product is R-(?)-3-(3-diisopropylamino-phenyl-propyl)-4-hydroxy-benzoic acid methyl ester.
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: February 22, 2005
    Assignee: Schwarz Pharma AG
    Inventor: Claus Meese
  • Publication number: 20040186061
    Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compouds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Type: Application
    Filed: January 27, 2004
    Publication date: September 23, 2004
    Applicant: Schwarz Pharma AG
    Inventors: Claus Meese, Bengt Sparf
  • Patent number: 6783769
    Abstract: The invention relates to a transdermal therapeutic system (TTS) for transcutaneously administering tolterodine over a period of several days and to a method for producing the same. The TTS contains a self-adhesive layer-shaped matrix composition which contains a (meth)acrylate copolymer comprising ammonium groups. The TTS also contains at least one plasticizer and up to 25 wt, % of tolterodine.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: August 31, 2004
    Assignee: Schwarz Pharma AG
    Inventors: Christoph Arth, Claus Meese, Dietrich Wilhelm Schacht, Hans-Michael Wolff
  • Patent number: 6713464
    Abstract: The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.
    Type: Grant
    Filed: January 2, 2001
    Date of Patent: March 30, 2004
    Assignee: Schwarz Pharma AG
    Inventors: Claus Meese, Bengt Sparf
  • Patent number: 5661129
    Abstract: The invention relates to novel nitrates containing a disulphide group, and to processes for their preparation. The compounds can be used for the therapy of disorders of the cardiovascular system.
    Type: Grant
    Filed: December 5, 1995
    Date of Patent: August 26, 1997
    Assignee: Schwarz Pharma AG
    Inventors: Martin Feelisch, Hilmar Bokens, Jochen Lehmann, Claus Meese, Klaus Sandrock